Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring ...

12 October 2026 · By · Wire by Fusion42

Published

12 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at markets.businessinsider.com →

◆ Verified

Fusion42 · 12 October 2026 · Fusion42 review

Humacyte announced interim Phase 3 trial results for its acellular tissue engineered vessel (ATEV) as hemodialysis access in women, accepted for a late-breaking presentation at ASN Kidney Week 2026. The company plans to submit a supplemental Biologics License Application to the FDA this quarter to expand ATEV’s use for arteriovenous (AV) access for hemodialysis.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face a shifting approval landscape as Humacyte's engineered vessel targets a persistent dialysis access problem for women. This FDA label expansion could open a new market segment needing better vascular access solutions.

◆ Coverage

1 source · 12 Oct 2026

◆ Related on Wire

◆ Topics

Biotechhemodialysisclinical-trialregulatory-submissionbiotechwomen-health